TY - JOUR T1 - Breadth of concomitant immune responses underpinning viral clearance and patient recovery in a non-severe case of COVID-19 JF - medRxiv DO - 10.1101/2020.02.20.20025841 SP - 2020.02.20.20025841 AU - Irani Thevarajan AU - Thi HO Nguyen AU - Marios Koutsakos AU - Julian Druce AU - Leon Caly AU - Carolien E van de Sandt AU - Xiaoxiao Jia AU - Suellen Nicholson AU - Mike Catton AU - Benjamin Cowie AU - Steven YC Tong AU - Sharon R Lewin AU - Katherine Kedzierska Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/23/2020.02.20.20025841.abstract N2 - We report the kinetics of the immune response in relation to clinical and virological features of a patient with mild-to-moderate coronavirus disease-19 (COVID-19) requiring hospitalisation. Increased antibody-secreting cells, follicular T-helper cells, activated CD4+ and CD8+ T-cells and IgM/IgG SARS-CoV-2-binding antibodies were detected in blood, prior to symptomatic recovery. These immunological changes persisted for at least 7 days following full resolution of symptoms, indicating substantial anti-viral immunity in this non-severe COVID-19.Competing Interest StatementSRL’s institution has received funding for investigator initiated research grants from Gilead Sciences, Merck, Viiv Healthcare and Leidos. She has received honoraria for participation in advisory boards and educational activities for Gilead Sciences, Merck, Viiv Healthcare and Abbvie.Clinical TrialN/AFunding StatementThis work was funded by the Australian National Health and Medical Research Council (NHMRC) Investigator Grant to KK (#1173871). CES has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 792532 and University of Melbourne McKenzie Fellowship laboratory support. KK is supported by a NHMRC Senior Research Fellowship Level B (#1102792) and SRL is supported by an NHMRC Practitioner Fellowship and an NHMRC program grant. SYCT is supported by a NHMRC Career Development Fellowship (#1145033). XJ is supported by China Scholarship Council-University of Melbourne joint Scholarship.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability The data that support the findings of this study are available from the corresponding author upon request. Raw FACS data are shown in the manuscript. ER -